Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Neurexis Therapeutics Awarded NIH Phase I SBIR Grant to Accelerate IND-Enabling Studies of Neuroprotective Therapeutic | ||
By: PR Newswire Association LLC. - 14 Oct 2021 | Back to overview list |
|
AURORA, Colo., Oct. 14, 2021 /PRNewswire-PRWeb/ -- Neurexis Therapeutics, Incorporated, announces it has been awarded a $496,145 grant from the National Institute of Neurological Disorders and Stroke (NINDS). The grant will advance the preclinical development of the company's innovative therapeutic peptide to prevent brain damage following Global Cerebral Ischemia (GCI). GCI is caused by drowning, suffocation, or the loss of blood flow to the brain due to cardiac arrest, sickle cell anemia, congenital heart defects, high-risk vascular surgery, coronary disease, and other complications. VIC Technology Venture Development formed Neurexis in early 2020 based on the efforts of Dr. Ulli Bayer at the University of Colorado Anschutz Medical Campus to create an optimized drug called tatCN19o. In both small and large animal studies, this peptide therapeutic prevents brain cell death and the resulting cognitive and behavioral problems caused by GCI. "We are encouraged by the support provided by NIH to move this promising, transformative product towards the clinic," said Dr. Michael Artinger, CEO of Neurexis Therapeutics. "In addition to improving the quality of life for patients experiencing GCI, tatCN19o may also provide benefit for ischemic stroke survivors, those suffering from traumatic brain injury, as well as other conditions." About Neurexis Therapeutics, Inc. About VIC Technology Venture Development, LLC Media Contact Michael Artinger, Neurexis Therapeutics, 1-720-771-6670, michael.artinger@neurexistherapeutics.com
SOURCE Neurexis Therapeutics |
||
|
||
Copyright 2021 PR Newswire Association LLC. | Back to overview list |